

Evaluation of the Effects of Two Dietary Supplement Formulations on the Lipid Profile in Mild Hypercholesterolemia

NCT06810466

Status	RECRUITING
Phase	Not Applicable
Sponsor	IBSA Farmaceutici Italia Srl
Enrollment	99 participants

Key Eligibility Criteria

Inclusion (4)

- Prevention of cardiovascular disease
- Low cardiovascular risk ($< 5\%$)
- Sub-optimal serum levels of LDL-C (130-136 mg/dl; 3.37-4.14 mmol/l) and/or non-HDL-C (160-190 mg/dl; 4.14-4.92 mmol/l) at T-2
- Signature of informed consent.

Exclusion (7)

- Patients with cardiovascular disease (in secondary prevention) or at risk of cardiovascular disease after 10 years (cardiovascular risk ≥ 5)
- diabetes mellitus
- Taking hypolipemiant, supplements or drugs that may involve lipid metabolism
- Hypertension treatment not stabilized for at least 3 months
- History of ongoing kidney, thyroid, gastrointestinal, muscle or liver disease
- ... and 2 more (see full listing online)

Locations (1 total)

S. Orsola-Malpighi University Hospital, Bologna, Italy, Italy